CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1,768 enrolled
Drug / intervention
Florbetapir F 18drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01518374
NCT01518374Phase 2Completed
CompareCT.gov

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

Avid Radiopharmaceuticals·interventional·Posted Jan 26, 2012·Updated Jul 18, 2018

In Brief

A Phase 2 clinical trial evaluating Florbetapir F 18 for Alzheimer Disease and 2 related conditions. Completed, enrolled 1,768 participants across 26 sites.

Detailed Summary

This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol) such as longitudinal studies of aging and studies of biomarkers for neurodegenerative diseases.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 26, 2012
Enrollment StartDec 1, 2009
Primary CompletionMay 3, 2017
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 14.4 years ago

Interventions

Florbetapir F 18drug

370 MBq (10 mCi)